Payment overview · 2025
General Payments
$25,660.30
40 reported records · 8 companies
Healthcare provider profile · identity verified
Christopher S Joncas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FALL RIVER, MA · NPI 1336136456
Verified facts
What the public records show
CMS Open Payments records show Christopher S Joncas, MD received $25,660.30 in general payments during 2025 across 40 reported records.
Neurocrine BioSciences, Inc. accounted for 99.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25,501.47 | 99.4% | 32 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.02 | 0.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.68 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.11 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.72 | 0.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.38 | 0.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.00 | 0.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.92 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,190.00 | 6 |
| Consulting Fee | $6,375.00 | 1 |
| Travel and Lodging | $2,582.07 | 9 |
| Food and Beverage | $1,513.23 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25,379.49 | 31 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $61.70 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 87 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
87 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
87 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1925 | 281 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1378 | 153 |
| Trazodone Hcl | Trazodone Hcl | 1341 | 125 |
| Omeprazole | Omeprazole | 1282 | 194 |
| Lisinopril | Lisinopril | 1259 | 226 |
| Furosemide | Furosemide | 1110 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 950 | 175 |
| Eliquis | Apixaban | 747 | 76 |
| Donepezil Hcl | Donepezil Hcl | 731 | 51 |
| Sertraline Hcl | Sertraline Hcl | 715 | 98 |
| Gabapentin | Gabapentin | 711 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 668 | 100 |
| Simvastatin | Simvastatin | 620 | 100 |
| Mirtazapine | Mirtazapine | 538 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 513 | 101 |
| Allopurinol | Allopurinol | 509 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 501 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 413 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 410 | 51 |
| Meloxicam | Meloxicam | 402 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 393 | 41 |
| Losartan Potassium | Losartan Potassium | 386 | 71 |
| Memantine Hcl | Memantine Hcl | 376 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 347 | 76 |
| Prednisone | Prednisone | 339 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 334 | 53 |
| Metformin Hcl | Metformin Hcl | 332 | 54 |
| Lorazepam | Lorazepam | 307 | 72 |
| Potassium Chloride | Potassium Chloride | 284 | 32 |
| Carvedilol | Carvedilol | 275 | 47 |
| Atenolol | Atenolol | 272 | 38 |
| Januvia | Sitagliptin Phosphate | 263 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 256 | 44 |
| Levetiracetam | Levetiracetam | 243 | 19 |
| Divalproex Sodium | Divalproex Sodium | 229 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 217 | 47 |
| Alprazolam | Alprazolam | 214 | 35 |
| Alendronate Sodium | Alendronate Sodium | 209 | 25 |
| Finasteride | Finasteride | 209 | 31 |
| Metformin Hcl Er | Metformin Hcl | 206 | 50 |
| Ezetimibe | Ezetimibe | 178 | 21 |
| Irbesartan | Irbesartan | 173 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 61 |
| Montelukast Sodium | Montelukast Sodium | 172 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 169 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 163 | 16 |
| Tradjenta | Linagliptin | 160 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 157 | 28 |
| Nystatin | Nystatin | 151 | 66 |
| Olanzapine | Olanzapine | 149 | 12 |
| Jardiance | Empagliflozin | 148 | 17 |
| Buspirone Hcl | Buspirone Hcl | 147 | 26 |
| Tramadol Hcl | Tramadol Hcl | 147 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 139 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 139 | 16 |
| Xarelto | Rivaroxaban | 139 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 129 | 25 |
| Clonazepam | Clonazepam | 127 | 28 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 127 | suppressed |
| Lamotrigine | Lamotrigine | 125 | 12 |
| Celecoxib | Celecoxib | 123 | 11 |
| Bumetanide | Bumetanide | 122 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 33 |
| Lovastatin | Lovastatin | 119 | 15 |
| Meclizine Hcl | Meclizine Hcl | 118 | 25 |
| Latanoprost | Latanoprost | 110 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 22 |
| Albuterol Sulfate | Albuterol Sulfate | 100 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 100 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 57 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 11 |
| Baclofen | Baclofen | 89 | 12 |
| Repaglinide | Repaglinide | 89 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 88 | 33 |
| Nifedipine Er | Nifedipine | 88 | suppressed |
| Rexulti | Brexpiprazole | 87 | suppressed |
| Sucralfate | Sucralfate | 85 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 83 | 80 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 83 | 12 |
| Ozempic | Semaglutide | 83 | 15 |
| Glimepiride | Glimepiride | 82 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 79 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 78 | suppressed |
| Valsartan | Valsartan | 78 | 15 |
| Famotidine | Famotidine | 77 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 71 | 17 |
| Lactulose | Lactulose | 71 | 11 |
| Spironolactone | Spironolactone | 71 | 14 |
| Myrbetriq | Mirabegron | 70 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 70 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 19 |
| Ondansetron Odt | Ondansetron | 69 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 36 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 65 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 62 | 14 |
| Levofloxacin | Levofloxacin | 62 | 43 |
| Rivastigmine | Rivastigmine Tartrate | 62 | suppressed |
| Ursodiol | Ursodiol | 62 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 58 | suppressed |
| Trulicity | Dulaglutide | 58 | 16 |
| Glipizide | Glipizide | 57 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 57 | suppressed |
| Sotalol | Sotalol Hcl | 55 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 20 |
| Hydrocortisone | Hydrocortisone | 51 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 51 | suppressed |
| Timolol Maleate | Timolol Maleate | 51 | suppressed |
| Diazepam | Diazepam | 50 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 50 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 49 | suppressed |
| Dofetilide | Dofetilide | 49 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 49 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 33 |
| Topiramate | Topiramate | 48 | suppressed |
| Rybelsus | Semaglutide | 47 | suppressed |
| Azithromycin | Azithromycin | 46 | 36 |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Lansoprazole | Lansoprazole | 46 | suppressed |
| Cephalexin | Cephalexin | 45 | 27 |
| Ibuprofen | Ibuprofen | 45 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 16 |
| Risperidone | Risperidone | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Linzess | Linaclotide | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 16 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 41 | suppressed |
| Ketoconazole | Ketoconazole | 41 | 11 |
| Mounjaro | Tirzepatide | 41 | 11 |
| Naproxen | Naproxen | 41 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 39 | suppressed |
| Budesonide | Budesonide | 39 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 39 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 13 |
| Atropine Sulfate | Atropine Sulfate | 37 | 27 |
| Calcitriol | Calcitriol | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Etodolac | Etodolac | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 34 | 27 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Clonidine | Clonidine | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 31 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 24 |
| Xtampza Er | Oxycodone Myristate | 29 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Admelog Solostar | Insulin Lispro | 26 | suppressed |
| Jantoven | Warfarin Sodium | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Nystop | Nystatin | 24 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 23 | suppressed |
| Exemestane | Exemestane | 23 | suppressed |
| Fluocinonide | Fluocinonide | 23 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Leflunomide | Leflunomide | 23 | suppressed |
| Propylthiouracil | Propylthiouracil | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Letrozole | Letrozole | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Trimethoprim | Trimethoprim | 22 | suppressed |
| Cartia Xt | Diltiazem Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Bicalutamide | Bicalutamide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 18 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Rhopressa | Netarsudil Mesylate | 18 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | 14 |
| Fluconazole | Fluconazole | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Zafirlukast | Zafirlukast | 15 | suppressed |
| Etodolac Er | Etodolac | 14 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Meropenem | Meropenem | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Relistor | Methylnaltrexone Bromide | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25,660.30 · 40 records | Neurocrine BioSciences, Inc. | AREXVY, INGREZZA, INSPIRE, Ozempic, REXULTI, Rybelsus, SHINGRIX, XIFAXAN, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error